A leadership transition in the US Food & Drug Administration Office of Immunology & Inflammation will test the durability of the new drug review structure implemented by the agency’s Center for Drug Evaluation & Research at the start of the current decade.
Former rheumatology division Director Nikolay Nikolov is now acting director of OII, succeeding Julie Beitz, who retired after 30 years...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?